Polyoxidonium® helps in the treatment of ENT diseases in children and adults

At the VIII All-Russian Forum of Otolaryngologists "Interdisciplinary Approach to the Treatment of Head and Neck Diseases" held in Moscow, issues of increasing the effectiveness of treatment of infectious and inflammatory diseases of the ENT organs in children and adults were discussed. Particular attention was paid to approaches to the treatment of adenoiditis and other diseases of the nasopharynx in children and adults.

Chronic adenoiditis, according to research, affects up to 75% of children aged 3 to 10 years^[1]. The disease not only leads to frequent upper respiratory tract infections, but can also cause complications including sinusitis, ear infections, and even obstructive sleep apnea syndrome^[1]. In this regard, the role of local immunity and approaches to strengthening it were discussed at the forum.

Olga Vitalievna Karneeva, Dr. habil. med., Professor of the Department of Otorhinolaryngology, Federal Postgraduate Training, N.I. Pirogov Russian National Research Medical University, Deputy Director for Academic and Scientific Work at the National Medical Research Center of Otolaryngology at the Federal Medical and Biological Agency of Russia, noted that adenotonsillar pathology, including chronic adenoiditis, is associated with frequent respiratory infections and increases the risk of developing more serious complications. She stressed the importance of strengthening local immunity, especially in children, as the tonsils play a key role in protecting the body from infections.

One of the drugs presented at the forum was Polyoxidonium^® (azoximer bromide), which has long been used in clinical practice to strengthen local immunity and reduce inflammatory processes in the nasopharynx. The use of azoximer bromide has shown good results in restoring nasal breathing and reducing the symptoms of adenoiditis.

One study, the results of which were published in the international journal BMJ Paediatrics Open, involved 2,463 children with inflammatory diseases of the nasopharynx^[2]. In 90% of children, after a ten-day course of treatment, nasal breathing was restored, and symptoms of adenoiditis were relieved in 80% of patients^[2]. The use of azoximer bromide also contributed to a reduction in the incidence of ARI. In long-term observations, the incidence of acute respiratory viral infections in children decreased from 5–8 episodes to 2–3 per year^[2].

The forum also discussed the possibility of using azoximer bromide to reduce inflammation and prevent complications in infectious diseases in adults. Clinical case studies involving more than 16,000 patients have confirmed that the use of the drug helps quickly relieve the symptoms of inflammatory diseases of the respiratory tract, including a decrease in fever, sore throat and other symptoms of intoxication^[3].